Major Depressive Disorder Clinical Trial
— DEPCOROfficial title:
Sensory and Psychomotor Profile in Depression
Verified date | July 2021 |
Source | Centre Hospitalier Esquirol |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Despite a possible psychomotor retardation during a depressive episode, standardized psychomotor assessment is rare. So, other possible psychomotor disorders or neurological "soft signs" are not known in depression. The investigator propose in this study to explore the psychomotor characteristics of patients with a major depressive disorder from the realization of a psychomotor assessment in comparison with adult without depressive disorder (control). It will be specifically assess muscle tone, gross motor skills, praxis, body schema and the body image and the perceptions.
Status | Completed |
Enrollment | 50 |
Est. completion date | October 15, 2019 |
Est. primary completion date | March 23, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - major depressive disorder according to the DSM-5 - aged to 18 from 65 years old Exclusion Criteria: - psychiatric comorbidity (bipolar, addiction, eating disorder, personality disorder, obsessional compulsive disorder) - antipsychotic drug - taken care in psychomotor therapy previously - electroconvulsive therapy - medical history of neurologic disease, neurodevelopmental disorder, sensory disability - Constraint Hospitalization - under legal protection - pregnant - lack of consent |
Country | Name | City | State |
---|---|---|---|
France | Centre Hospitalier Esquirol | Limoges |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Esquirol |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | % of patients with a distinctive feature at the sensory profile questionnaire from the AASP | Scores at the AASP psychomotor battery are considered. A failure is considered from a result <1SD compared to the control group. | At inclusion | |
Primary | % of patients with a failure at the muscle tone test from the NP-MOT battery | Scores at the NP-MOT psychomotor battery are considered. A failure is considered from a result <1SD compared to the control group. | At inclusion | |
Primary | % of patients with a failure at the gross motor test from the NP-MOT battery | Scores at the NP-MOT psychomotor battery are considered. A failure is considered from a result <1SD compared to the control group. | At inclusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |